EU SCENIHR yet to adopt second opinion on safety of PIP breast implants
This article was originally published in Clinica
Further delays have stalled EU regulators from adopting the second opinion, issued by the European Commission’s scientific committee that assesses emerging and newly identified health risks (SCENIHR), on the safety of PIP silicone breast implants.
You may also be interested in...
Those marketing products covered under the EU’s MDR and IVD Regulations have plenty of reading this month to help them prepare. More details have also emerged about the UK’s regulatory future.
Where are the biggest challenges for notified bodies and manufacturers now there is some experience with the MDR, and can the sector manage the new regulatory requirements successfully?
The European Commission has finally published detailed guidance on the EU IVDR’s classification rules. The IVDR’s completely new classification regime means guidance is urgently needed.